ERAS on Postoperative Recovery After Laparoscopic Distal Gastrectomy
Effectiveness of Enhanced Recovery After Surgery (ERAS) on Postoperative Recovery After Laparoscopic Distal Gastrectomy: An Open-labeled Randomized Controlled Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Hojin Lee, MD, PhD
- Phone Number: 82-2-2072-2467
- Email: zenerdiode03@gmail.com
Study Contact Backup
- Name: Do Joong Park, MD, PhD
- Phone Number: 82-2-2072-2318
- Email: djparkmd@snu.ac.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, KS013
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients scheduled to undergo elective laparoscopic distal gastrectomy
- American Society of Anesthesiologists (ASA)physical classification I-II
- ECOG Performance Status Scale 0 or 1
- Willingness and ability to sign an informed consent document
Exclusion Criteria:
- Patients with chronic pain
- Gastrectomy with combined resection of other organs
- Patients with history of upper abdominal surgery
- Allergies to anesthetic or analgesic medications (fentanyl, ropivacaine, acetaminophen, NSAIDs)
- Medical or psychological disease that can affect the treatment response
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ERAS group
Perioperative care for laparoscopic distal gastrectomy is managed according to ERAS protocol.
|
The ERAS protocol involves a pre-admission patient education using audiovisual videos, the reduction of perioperative fasting time with administration of preoperative carbohydrate loading and early resumption of oral feeding after surgery, multimodal postoperative nausea and vomiting prevention, early removal of the nasogastric tube and urinary catheter, and multimodal analgesia to minimize opioid consumption after surgery.
|
|
No Intervention: Conventional group
Perioperative care for laparoscopic distal gastrectomy is managed according to our current perioperative practice.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of the Quality of recovery-15 during the first 72 hours after surgery
Time Frame: postoperative 24, 48, and 72 hours
|
Korean version of Quality of recovery-15 questionnaire (0-150): 0, "very poor recovery"; 150, "excellent recovery"
|
postoperative 24, 48, and 72 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Postoperative pain score
Time Frame: postoperative 24, 48, and 72 hours
|
11-pointed NRS pain score at resting/coughing NRS (0-10): 0,"no pain"; 10, "worst pain imaginable"
|
postoperative 24, 48, and 72 hours
|
|
Postoperative gastrointestinal dysfunction
Time Frame: postoperative 24, 48, and 72 hours
|
I-FEED score 3 points or more (postoperative gastrointestinal intolerance and dysfunction)
|
postoperative 24, 48, and 72 hours
|
|
Total fentanyl consumption
Time Frame: From the end of surgery to 24, 48, and 72 hours postoperatively
|
postoperative fentanyl consumption (mcg) via IV patient controlled analgesia
|
From the end of surgery to 24, 48, and 72 hours postoperatively
|
|
Postoperative nausea and vomiting
Time Frame: From the end of surgery to 24, 48, and 72 hours postoperatively
|
Incidence of postoperative nausea and vomiting (%)
|
From the end of surgery to 24, 48, and 72 hours postoperatively
|
|
Recovery time
Time Frame: Evaluate every hour starting from 9A on the postoperative day 3 up to discharge
|
Postoperative time satisfying the following four criteria: (1) tolerance of soft blended diet (SBD) for 24 h; (2) safe ambulation of 600 m without assistance; (3) Adequate pain control (NRS ≤ 3) with oral non opioid analgesics; and (4) No abnormal physical findings or laboratory test
|
Evaluate every hour starting from 9A on the postoperative day 3 up to discharge
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Do Joong Park, MD, PhD, Seoul National University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 2207-206-1346
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.